Page 164 - Read Online

However, recent advances in automated analyzers have In the future, a prospective study of a large patient
resulted in a decline in microscopic observation, so there population is needed to determine whether HCC with
is a tendency for Howell-Jolly bodies, which can only portal hypertension should be treated with simultaneous
be confirmed visually to be overlooked, and to be less splenectomy or simultaneous PSE.
emphasized in clinical settings. Nevertheless, the appearance
of Howell-Jolly bodies is associated with an increased risk of Financial support and sponsorship
PSS/OPSI in patients with reduced splenic function, so the Nil.
fact that these bodies were frequently observed in peripheral
erythrocytes after PSE without any relationship to residual Confl ict of interest
spleen volume or the splenic infarction rate emphasizes There is no conflict of interest.
the need to visually determine the presence or absence
of these entities and when they are present to administer REFERENCES
pneumococcal vaccine to prevent severe infection.
1. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood
cytopenias (hypersplenism) in patients with nonalcoholic chronic liver
Moreover, PSE and splenectomy sometimes induced PVT. PVT disease. Am J Gastroenterol 2000;95:2936-9.
is a severe, potentially fatal complication. Some predictive 2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical
[19]
factors of PVT are reported for early detection. [20,21] Early frontiers and perspectives. Gut 2014;63:844-55.
detection of PVT and prompt anticoagulation are effective 3. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S,
Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M,
to avoid serious consequences of PVT. It is necessary to Ogasawara S, Yamashita T, Minami T; Liver Cancer Study Group
[22]
perform PSE recognizing to these problems with reduced of Japan. Transarterial chemoembolization failure/refractoriness:
splenic function after PSE. JSH-LCSGJ criteria 2014 update. Oncology 2014;87 Suppl 1:22-31.
4. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M.
Percutaneous ethanol injection therapy for liver tumors. Eur J
CONCLUSION Ultrasound 2001;13:95-106.
5. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T,
Compared to splenectomy, some advantages of PSE are Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation
that it is minimally invasive, can preserve splenic function, for hepatocellular carcinoma. An analysis of 1000 cases. Cancer
2005;103:1201-9.
and only rarely causes OPSI and PVT. However, PSE also has 6. Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer.
the risk of complications such as fever, abdominal pain, Liver Cancer 2014;3:125-31.
vomiting, and ascites/pleural effusion, as well as serious 7. Linton RR, Jones CM, Volwiler W. Portal hypertension; the treatment
symptoms including splenic abscess, and peritonitis, so the by splenectomy and splenorenal anastomosis with preservation of the
kidney. Surg Clin North Am 1947;27:1162-70.
decision as to whether to perform the procedure should be a 8. Spigos DG, Jonasson O, Mozes M, Capek V. Partial splenic
carefully considered one. Myelosuppressed patients receiving embolization in the treatment of hypersplenism. AJR Am J Roentgenol
anticancer drugs or immuno-suppressants are even more 1979;132:777-82.
susceptible to the risk of infection. HCC is a tumor-bearing 9. Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T,
Takayama T, Makuuchi M. Splenectomy in patients with hepatocellular
condition, so it is believed to be essential to attempt to carcinoma and hypersplenism. J Am Coll Surg 2000;190:446-50.
minimize the patient’s susceptibility to infection due to the 10. Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late
asplenia or significantly reduced splenic function. There is no postsplenectomy infection. Br J Surg 1991;78:716-21.
clear evidence to suggest whether PSE should be performed 11. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV,
Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An
simultaneously with HCC treatment or at a different time. evaluation of current recommendations. JAMA 1993;270:1826-31.
The decision will obviously be influenced by various aspects 12. Maddison FE. Embolic therapy of hypersplenism. Invest Radiol
of the treatment strategy including the location and size of 1973;8:280-1.
the HCC and any additional therapies, and by the condition 13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin 2011;61:69-90.
of the patient’s cirrhosis. Still, simultaneous TACE combined 14. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K,
with PSE represents a safe and effective approach in patients Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report
who cannot undergo concomitant RFA therapy. Furthermore, of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in
Japan. Hepatol Res 2007;37:676-91.
TACE combined with PSE is capable of maintaining a hepatic 15. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T,
functional reserve. This finding suggests that TACE combined Kamimura T. Prevention of intrahepatic distant recurrence by
with PSE may represent a treatment strategy for HCC transcatheter arterial infusion chemotherapy with platinum agents for
associated with portal hypertension and a multidisciplinary stage I/II hepatocellular carcinoma. Cancer 2011;117:4018-25.
treatment modality for HCC associated with cirrhosis 16. Ishikawa T, Kubota T, Abe S, Watanabe Y, Sugano T, Inoue R, Iwanaga A,
Seki K, Honma T, Yoshida T. Hepatic arterial infusion chemotherapy
characterized by thrombocytopenia. with cisplatin before radical local treatment of early hepatocellular

Hepatoma Research | Volume 1 | Issue 3 | October 15, 2015 157